Paragon 28 Growth Driven by New Product Cadence

Paragon 28 reported 3Q22 orthopedic sales of $46 million, +28.3% compared to the third quarter of 2021. The company raised its 2022 full-year sales guidance to $179.5 million, representing 22% growth.

In the U.S., Paragon 28's traction with new product launches drove increased surgeon adoption and attracted new sales talent. The company...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us